# US 2003/0204085 A1 · 3, 4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0204085 A1
- Document ID: US20030204085A1
- Status: Published application
- Kind: A1
- Application number: 10/208,426
- Filed: 2002-07-30
- Published: 2003-10-30
- Earliest claimed: 2001-02-02
- Inventors: Arthur G. Taveras; Cynthia J. Aki; Richard W. Bond; Jianping Chao; Michael Dwyer; Johan A. Ferreira; Jonathan A. Pachter; John J. Baldwin; Bernd Kaiser; Ge Li; J. Robert Merritt; Kingsley H. Nelson JR.; Laura L. Rokosz
- Web page: https://patentgrep.com/patent/US20030204085A1

## CPC

- C07D 207/08: with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
- C07C 225/20: having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
- C07C 229/42: with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
- C07C 229/64: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C 237/36: having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C 237/44: having carbon atoms of carboxamide groups, amino groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C 255/59: the carbon skeleton being further substituted by singly-bound oxygen atoms
- C07C 271/20: to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
- C07C 311/08: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07C 311/21: having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
- C07D 205/04: having no double bonds between ring members or between ring members and non-ring members
- C07D 207/16: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 211/60: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 213/74: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 213/89: with hetero atoms directly attached to the ring nitrogen atom
- C07D 231/38: Nitrogen atoms (nitro radicals C07D231/16)
- C07D 235/06: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D 239/42: One nitrogen atom (nitro radicals C07D239/30)
- C07D 249/18: Benzotriazoles
- C07D 277/28: Radicals substituted by nitrogen atoms
- C07D 277/42: Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
- C07D 285/08: 1,2,4-Thiadiazoles; Hydrogenated 1,2,4-thiadiazoles
- C07D 295/13: to an acyclic saturated chain
- C07D 295/135: with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/192: from aromatic carboxylic acids
- C07D 295/205: Radicals derived from carbonic acid
- C07D 317/66: Nitrogen atoms not forming part of a nitro radical
- C07D 333/38: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07C 2601/04: with a four-membered ring
- C07C 2601/14: The ring being saturated
- C07C 2602/10: the other ring being six-membered, e.g. tetraline
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

Disclosed are compounds of the formula: 1 or a pharmaceutically acceptable salt or solvate thereof. Also disclosed are the use of compounds of formula I for the treatment of chemokine-mediated diseases such as cancer, and acute and chronic inflammatory disorders.

## Claims

### Claim 1

A compound of the formula
497
and the pharmaceutically acceptable salts and solvates thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
498
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
s) —(CH2)qN(R20)(C(O)OR21) wherein: q is 1-6; R20 is selected from the group consisting of H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein: q is 1-6; R22 is selected from the group consisting of BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is selected from the group consisting of:
499
provided that R3 for this group is selected from the group consisting of: —C(O)NR7R8,
500 501 502
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8 (e.g., —C(O)NHOR8, and —C(O)NR7OH), —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
503
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
each R3 and each R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2,
504
cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is 1-6; R24 is selected from the group consisting of: H, alkyl and aryl; r is 2 to 6; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
505
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
each R5 and each R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
506
p) alkyl substituted with one or more —OH,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
each R7 and each R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic, substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and substituted R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8 form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A), —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R9 and each R10 are independently selected from the group consisting of: R7, hydrogen, halogen, —CF3, —OCF3, —NR7R8, —NR7C(O)NR7R8, —OH, —C(O)OR7, —SH, —SO(t)NR7R8,SO2R7, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —C(O)NR7R8, —C(O)NR7OR8, —OR7, —OC(O)R7, cyano, an unsubstituted heterocyclic acidic functional group, and a substituted heterocyclic acidic functional group; wherein there are 1 to 6 substituents on said substituted heterocyclic acidic functional group, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
507
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
R13 is COR7;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl; wherein there are 1 to 6 substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —C(O)NR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
R15 is selected from the group consisting of: hydrogen, —COOR7, —OR7, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, substituted heteroary, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, unsubstituted alkyl, substituted alkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heteroarylalkyl, and substituted heteroarylalkyl; and wherein there are 1 to 6 substituents on said substituted R15 groups and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
508
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A;
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
R30 is selected from the group consisting of: alkyl, cycloalkyl, —CN, —NO2, or —SO2R15A (provided that R15A is not H);
each R31 is independently selected from the group consisting of: unsubstituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted cycloalkyl; wherein there are 1 to 6 substituents on said substituted R31 groups and each substituent is independently selected from the group consisting of:
a) alkyl;
b) halogen; and
c) —CF3;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1 wherein A is selected from the group consisting of:
509 510
wherein:
k is 0 to 5;
l is 0 to 4;
m is 0 to 2;
n is 0 to 3;
p is 0 to 4;
each R11 and each R12 are independently selected from the group consisting of: H, —OH, halogen, cyano, —CF3, —OCF3, —NR7R8, —NR7C(O)NR7R8, —C(O)NR7R8, —CO2R7, —OR7, —SO(t)NR7R8, —NR7SO(t)R8, —COR7, substituted aryl, unsubstituted aryl, substituted alkyl, unsubstituted alkyl, substituted alkoxy, unsubstituted alkoxy, substituted arylalkyl, unsubstituted arylalkyl, substituted heteroaryl, unsubstituted heteroaryl, aryloxy, heteroarylalkyl, heteroarylalkoxy, heterocyclylalkyl, hydroxyalkyl, —(CH2)qN(R7)C(O)OR8 (wherein q is 1-6), and —O(CH2)qNR7R8 (wherein q is 1-6); wherein there are 1 to 6 substituents on said substituted R11 and substituted R12 groups and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
511
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected,
r) —N(R13A)SO2R14A.

### Claim 3 (depends on 1)

The compound according to claim 1 wherein B is
512
wherein:
R2 is hydrogen, OH, NHC(O)R7 or NHSO2R7;
R3 is —C(O)NR7R8;
R4 is hydrogen, NO2, CF3 or cyano,
R5 is hydrogen, halogen, NO2, cyano or CF3; and
R6 is hydrogen or CF3.

### Claim 4 (depends on 2)

The compound according to claim 2 wherein B is
513
wherein:
R2 is hydrogen, OH, NHC(O)R7 or NHSO2R7;
R3 is —C(O)NR7R8;
R4 is hydrogen, NO2, CF3 or cyano,
R5 is hydrogen, halogen, NO2, cyano or CF3; and
R6 is hydrogen or CF3.

### Claim 5 (depends on 1)

The compound of claim 1 wherein A is selected from the group consisting of:
514
wherein:
k is 0 to 5;
l is 0 to 4;
m is 0 to 2;
n is 0 to 3;
each R11 and each R12 are independently selected from the group consisting of: —OH, halogen, cyano, —CF3, —OCF3, —NR7R8, —NR7C(O)NR7R8, —C(O)NR7R8, —CO2R7, —OR7, —SO(t)NR7R8, —NR7SO(t)R8, —COR7, substituted aryl, unsubstituted aryl, substituted alkyl, unsubstituted alkyl, substituted alkoxy, unsubstituted alkoxy, substituted arylalkyl, unsubstituted arylalkyl, substituted heteroaryl, unsubstituted heteroaryl, aryloxy, heteroarylalkyl, heteroarylalkoxy, heterocyclylalkyl, hydroxyalkyl, —(CH2)qN(R7)C(O)OR8 (wherein q is 1-6), and —O(CH2)qNR7R8 (wherein q is 1-6); wherein there are 1 to 6 substituents on said substituted R11 and substituted R12 groups and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
515
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected; and
r) —N(R13A)SO2R14A (e.g., R13A is H and R14A is alkyl, such as methyl);
R11B is independently selected from the group consisting of: H, —OH, halogen, cyano, —CF3, —OCF3, —NR7R8, —NR7C(O)NR7R8, —C(O)NR7R8, —CO2R7, —OR7, —SO(t)NR7R8, —NR7SO(t)R8, —COR7, substituted aryl, unsubstituted aryl, substituted alkyl, unsubstituted alkyl, substituted alkoxy, unsubstituted alkoxy, substituted arylalkyl, unsubstituted arylalkyl, substituted heteroaryl, unsubstituted heteroaryl, aryloxy, heteroarylalkyl, heteroarylalkoxy, heterocyclylalkyl, hydroxyalkyl, —(CH2)qN(R7)C(O)OR8 (wherein q is 1-6), —O(CH2)qNR7R8 (wherein q is 1-6); wherein there are 1 to 6 substituents on said substituted R11 and substituted R12 groups and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
516
p) alkyl substituted with one or more —OH,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected; and
r) —N(R13A)SO2R14A (e.g., R13A is H and R14A is alkyl, such as methyl).

### Claim 6 (depends on 5)

The compound of claim 5 wherein B is
517
wherein:
R2 is hydrogen, OH, NHC(O)R7 or NHSO2R7;
R3 is —C(O)NR7R8;
R4 is hydrogen, NO2, CF3 or cyano,
R5 is hydrogen, halogen, or CF3; and
R6 is hydrogen or CF3.

### Claim 7 (depends on 3)

The compound of claim 3 wherein:
R2 is OH or NHSO2R7;
R4 is hydrogen, NO2 or cyano;
R5 is hydrogen, Cl or CF3; and
R6 is hydrogen or CF3.

### Claim 8 (depends on 7)

The compound of claim 7 wherein:
R2 is OH;
R4 is hydrogen; and
R6 is hydrogen.

### Claim 9 (depends on 4)

The compound of claim 4 wherein:
R2 is OH or NHSO2R7;
R4 is hydrogen, NO2 or cyano; and
R5 is hydrogen, Cl or CF3.

### Claim 10 (depends on 6)

The compound of claim 6 wherein
R2 is OH or NHSO2R7;
R4 is hydrogen, NO2 or cyano; and
R5 is hydrogen, Cl or CF3.

### Claim 11 (depends on 9)

The compound of claim 9 wherein:
R2 is OH;
R4 is hydrogen; and
R6 is hydrogen.

### Claim 12 (depends on 10)

The compound of claim 10 wherein
R2 is OH;
R4 is hydrogen; and
R6 is hydrogen.

### Claim 13 (depends on 1)

The compound of claim 1 wherein:
R2 is hydrogen, OH, NHC(O)R7 or NHSO2R7;
R3 is C(O)NR7R8;
R4 is hydrogen, NO2, CF3 or cyano;
R5 is hydrogen, halogen, cyano, NO2 or CF3; and
R6 is hydrogen or CF3.

### Claim 14 (depends on 1)

The compound of claim 1 wherein:
R2 is hydrogen, OH, NHC(O)R7 or NHSO2R7;
R3 is C(O)NR7R8;
R4 is hydrogen, NO2, CF3 or cyano;
R5 is hydrogen, halogen or CF3; and
R6 is hydrogen or CF3.

### Claim 15 (depends on 1)

The compound of claim 1 wherein:
R2 is OH;
R3 is C(O)NR7R8;
R4 is hydrogen;
R5 is hydrogen, Cl or CF3; and
R6 is hydrogen.

### Claim 16 (depends on 1)

The compound of claim 1 wherein substituent B is:
518
R2, R4, R5 and R6 are as defined for the novel compounds of formula I;
R7 and R8 are each independently selected from the group consisting of: H and alkyl; or
R7 and R8 taken together with the nitrogen to which they are bound form a heterocyclic ring, said heterocyclic ring being unsubstituted or substituted.

### Claim 17 (depends on 1)

The compound of claim 1 wherein substituent B is:
519
R2, R4, R5 and R6 are as defined for the novel compounds of formula I;
R7 and R8 are each independently selected from the group consisting of: H and alkyl; or
R7 and R8 taken together with the nitrogen to which they are bound form an unsubstituted heterocyclic.

### Claim 18 (depends on 1)

The compound of claim 1 wherein B is selected from the group consisting of:
520
wherein:
R2 is selected from the group consisting of: H, OH, —NHC(O)R7 and —NHSO2R7;
R3 is selected from the group consisting of: —C(O)NR7R8—SO2NR7R8, —NO2, cyano, and —SO2R7;
R4 is selected from the group consisting of: H, —NO2, cyano, —CH3 or —CF3;
R5 is selected from the group consisting of: H, —CF3, —NO2, halogen and cyano; and
R6 is selected from the group consisting of: H, alkyl and —CF3;
R10 is selected from the group consisting of: H, halogen and alkyl; and
each R7 and R8 is independently selected from the group consisting of: methyl and ethyl.

### Claim 19 (depends on 1)

The compound of claim 1 wherein B is
521
R3 is selected from the group consisting of:
522
R2 is —OH.

### Claim 20 (depends on 1)

The compound of claim 1 wherein B is
523
R2 is —OH, R7 and R8 are the same or different alkyl group.

### Claim 21

A compound of formula I
524
or a pharmaceutically acceptable salt or solvate thereof, wherein
525 526 527

### Claim 22 (depends on 21)

The compound of claim 21 wherein the compound is:
528

### Claim 23 (depends on 21)

The compound of claim 21 wherein the compound is:
529

### Claim 24 (depends on 21)

The compound of claim 21 wherein the compound is:
530

### Claim 25 (depends on 21)

The compound of claim 21 wherein the compound is:
531

### Claim 26 (depends on 21)

The compound of claim 21 wherein the compound is:
532

### Claim 27 (depends on 21)

The compound of claim 21 wherein the compound is:
533

### Claim 28 (depends on 21)

The compound of claim 21 wherein the compound is:
534

### Claim 29 (depends on 21)

The compound of claim 21 wherein the compound is:
535

### Claim 30 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 31 (depends on 1)

A method of treating a chemokine-mediated disease, in a patient in need thereof, wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor in said patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 32 (depends on 1)

A method of treating a chemokine-mediated disease, in a patient in need thereof, wherein the chemokine binds to a CXC receptor in said patient, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 33 (depends on 31)

The method of claim 31 wherein said chemokine mediated disease is selected from the group consisting of: psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis or thrombosis, Alzheimer's disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayted type hypersensitivity reaction, atherosclerosis and cerebral and cardiac ischemia.

### Claim 34 (depends on 1)

A method of treating cancer, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 35 (depends on 1)

A method of treating cancer, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1, and administering to said patient at least one anti-cancer agent and/or radiation therapy.

### Claim 36 (depends on 35)

The method of claim 35, wherein said anti-cancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents, steroids and synthetics.

### Claim 37 (depends on 1)

A method of inhibiting angiogenesis, in a patient in need thereof, comprising administering to said patient an anti-angiogenic amount of a compound of claim 1.

### Claim 38 (depends on 1)

A method of inhibiting angiogenesis, in a patient in need thereof, comprising administering to said patient an anti-angiogenic amount of a compound of claim 1, and administering to said patient at least one known anti-angiogenic agent.

### Claim 39 (depends on 38)

The method of claim 38 wherein said known anti-angiogenic agent is selected from the group consisting of: Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, taxotere and Taxol.

### Claim 40 (depends on 1)

A method of treating a disease selected from the group consisting of: gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, kaposi's sarcoma associated virus and atherosclerosis, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of claim 1.

### Claim 41 (depends on 31)

The method of claim 31 wherein said chemokine mediated disease is an angiogenic ocular disease.

### Claim 42 (depends on 41)

The method of claim 41 wherein said angiogenic ocular disease is selected from the group consisting of: ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

### Claim 43 (depends on 34)

The method of claim 34 wherein said cancer is selected from the group consisting of: melanoma, gastric carcinoma or non-small cell lung carcinoma.

### Claim 44 (depends on 35)

The method of claim 35 wherein said cancer is selected from the group consisting of: melanoma, gastric carcinoma or non-small cell lung carcinoma.

### Claim 45 (depends on 44)

The method of claim 44, wherein the anti-cancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents, steroids and synthetics.

### Claim 46 (depends on 45)

The method of claim 45 wherein said anti-angiogenic agent is selected form the group consisting of: Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, taxotere and Taxol.

### Claim 47

A method of treating a chemokine-mediated disease, in a patient in need thereof, wherein the chemokine binds to a CXCR2 and/or CXCR1 receptor in said patient, comprising administering to said patient a therapeutically effective amount of a compound of formula I:
536
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
537
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A,
s) —(CH2)qN(R20)(C(O)OR21) wherein q is 1-6, R20 is selected from the group consisting of: H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl an alkyl group, and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein q is 1-6, R22 is selected from the group consisting of: BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is:
538
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8, —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
539
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A);
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2, cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is as defined above; R24 is selected from the group consisting of H, alkyl and aryl; r is as defined above; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
540
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R5 and R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
541
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R7 and R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic (e.g.,unsubstituted heterocycloalkyl), substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic); wherein there are 1 to 6 (e.g., 1 to 3) substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A, (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —CONR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups, and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or 2.

### Claim 48

A method of treating a chemokine-mediated disease, in a patient in need thereof, wherein the chemokine binds to a CXC receptor in said patient, comprising administering to said patient a therapeutically effective amount of a compound of formula I:
542
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
543
q) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A,
s) —(CH2)qN(R20)(C(O)OR21) wherein q is 1-6, R20 is selected from the group consisting of: H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl an alkyl group, and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein q is 1-6, R22 is selected from the group consisting of: BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is:
544
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8, —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
545
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A);
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2, cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is as defined above; R24 is selected from the group consisting of H, alkyl and aryl; r is as defined above; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
546
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R5 and R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
547
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R7 and R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic (e.g.,unsubstituted heterocycloalkyl), substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic), wherein there are 1 to 6 (e.g., 1 to 3) substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A, (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —CONR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups, and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or2.

### Claim 49 (depends on 47)

The method of claim 47 wherein said chemokine mediated disease is selected from the group consisting of: psoriasis, atopic dermatitis, asthma, chronic obstructive pulmonary disease, adult respiratory disease, arthritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, septic shock, endotoxic shock, gram negative sepsis, toxic shock syndrome, stroke, cardiac and renal reperfusion injury, glomerulonephritis or thrombosis, Alzheimer's disease, graft vs. host reaction, allograft rejections, malaria, acute respiratory distress syndrome, delayted type hypersensitivity reaction, atherosclerosis and cerebral and cardiac ischemia.

### Claim 50

A method of treating cancer, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of formula I:
548
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
549
r) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
s) —N(R13A)SO2R14A,
s) —(CH2)qN(R20)(C(O)OR21) wherein q is 1-6, R20 is selected from the group consisting of: H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl an alkyl group, and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein q is 1-6, R22 is selected from the group consisting of: BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is:
550
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8, —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
551
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A);
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2, cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is as defined above; R24 is selected from the group consisting of H, alkyl and aryl; r is as defined above; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
552
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R5 and R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
553
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R7 and R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic (e.g.,unsubstituted heterocycloalkyl), substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic); wherein there are 1 to 6 (e.g., 1 to 3) substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —CONR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups, and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or 2.

### Claim 51 (depends on 50)

The method of claim 50 further comprising the administration of at least one anti-cancer agent and/or radiation therapy.

### Claim 52 (depends on 51)

The method of claim 51, wherein said anti-cancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents, steroids and synthetics.

### Claim 53

A method of inhibiting angiogenesis, in a patient in need thereof, comprising administering to said patient an anti-angiogenic amount of a compound of formula I:
554
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
555
s) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
t) —N(R13A)SO2R14A,
s) —(CH2)qN(R20)(C(O)OR21) wherein q is 1-6, R20 is selected from the group consisting of: H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl an alkyl group, and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein q is 1-6, R22 is selected from the group consisting of: BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is:
556
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8, —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
557
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A);
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2, cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is as defined above; R24 is selected from the group consisting of H, alkyl and aryl; r is as defined above; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
558
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R5 and R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
i) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
559
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R7 and R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic (e.g.,unsubstituted heterocycloalkyl), substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic); wherein there are 1 to 6 (e.g., 1 to 3) substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —CONR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups, and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or 2.

### Claim 54 (depends on 53)

The method of claim 53 further comprising the administering to said patient at least one known anti-angiogenic agent.

### Claim 55 (depends on 54)

The method of claim 54 wherein said known anti-angiogenic agent is selected from the group consisting of: Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP-470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, taxotere and Taxol.

### Claim 56

A method of treating a disease selected from the group consisting of: gingivitis, respiratory viruses, herpes viruses, hepatitis viruses, HIV, kaposi's sarcoma associated virus and atherosclerosis, in a patient in need thereof, comprising administering to said patient a therapeutically effective amount of a compound of formula I:
560
or a pharmaceutically acceptable salt or solvate thereof, wherein:
A is selected from the group consisting of unsubstituted aryl, substituted aryl, unsubstituted heteroaryl and substituted heteroaryl; wherein said substituted groups have 1 to 6 substituents, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
561
t) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A,
s) —(CH2)qN(R20)(C(O)OR21) wherein q is 1-6, R20 is selected from the group consisting of: H, alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl; and R21 is selected from the group consisting of: alkyl, cycloalkyl, aryl, arylalkyl, heteroaryl, and heteroarylalkyl an alkyl group, and
t) —(CH2)qN(R22)(CH2)rN(R23)2 wherein q is 1-6, R22 is selected from the group consisting of: BOC, H and —C(O)R13A; r is 2 to 6; and each R23 is the same or different alkyl group;
B is:
562
R2 is selected from the group consisting of: hydrogen, —OH, —C(O)OH, —SH, —SO2NR7R8, —NHC(O)R7, —NHSO2NR7R8, —NHSO2R7, —NHR7, —C(O)NR7R8, —C(O)NR7OR8, —SO2OH, —OC(O)R7, —OR7, unsubstituted heterocyclic acidic functional group, and substituted heterocyclic acidic functional group; wherein said substituted heterocyclic acidic functional group is substituted with 1 to 6 substitutents selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
563
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A);
R3 and R4 are independently selected from the group consisting of: hydrogen, halogen, alkoxy, —OH, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —SO(t)NR7R8, —SO(t)R7, —C(O)NR7OR8, —C(O)NHR17, —(CH2)qN(R24)(CH2)rN(R25)2, cyano, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted heteroaryl, and substituted heteroaryl; wherein q is as defined above; R24 is selected from the group consisting of H, alkyl and aryl; r is as defined above; and each R25 is the same or different alkyl group; and wherein there are 1 to 6 substitutents on said substituted R3 and R4 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
564
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R5 and R6 are independently selected from the group consisting of: hydrogen, halogen, alkyl, alkoxy, —CF3, —OCF3, —NO2, —C(O)R7, —C(O)OR7, —C(O)NR7R8, —SO(t)NR7R8, —C(O)NR7OR8, cyano, unsubstituted aryl, substituted aryl unsubstituted heteroaryl, and substituted heteroaryl group; wherein there are 1 to 6 substituents on said substituted R5 and R6 groups, and each substituent is independently selected from the group consisting of:
a) —R13A,
b) halogen,
c) —CF3,
d) —COR13A,
e) —OR13A,
f) —NR13AR14A,
g) —NO2,
h) —CN,
i) —SO2R13A,
j) —SO2NR13AR14A,
k) —NR13ACOR14A,
l) —CONR13AR14A,
m) —NR13ACO2R14A,
n) —CO2R13A,
o)
565
p) alkyl substituted with one or more —OH groups,
q) alkyl substituted with one or more —NR13AR14A groups, and when there is more than one —NR13AR14A group each —NR13AR14A group is independently selected, and
r) —N(R13A)SO2R14A;
R7 and R8 are independently selected from the group consisting of: hydrogen, unsubstituted alkyl, substituted alkyl, unsubstituted aryl, substituted aryl, unsubstituted alkylaryl, substituted alkylaryl, unsubstituted arylalkyl, substituted arylalkyl, unsubstituted cycloalkyl, substituted cycloalkyl, carboxyalkyl, aminoalkyl, unsubstituted heteroaryl, substituted heteroaryl, unsubstituted heteroarylalkyl, substituted heteroarylalkyl, unsubstituted heterocycloalkylalkyl, substituted heterocycloalkylalkyl, unsubstituted cycloalkylalkyl, substituted cycloalkylalkyl, unsubstituted heterocyclic (e.g.,unsubstituted heterocycloalkyl), substituted heterocyclic, unsubstituted fluoroalkyl, and substituted fluoroalkyl; wherein there are 1 to 6 substituents on said substituted R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, hydroxyalkyl, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R7 and R8 taken together with the nitrogen atom to which they are bound to in the groups —C(O)NR7R8 and —SO2NR7R8, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing 1 to 3 additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R7 and R8 groups and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, cyano, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, aminoalkyl, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group;
each R13A and each R14A is independently selected from the group consisting of: H, unsubstituted or substituted alkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl, unsubstituted or substituted arylalkyl, unsubstituted or substituted heteroarylalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted cycloalkylalkyl, unsubstituted or substituted heterocyclic, unsubstituted or substituted fluoroalkyl, and unsubstituted or substituted heterocycloalkylalkyl (wherein “heterocyloalkyl” means heterocyclic); wherein there are 1 to 6 (e.g., 1 to 3) substituents on said substituted R13A and R14A groups and each substituent is independently selected from the group consisting of: alkyl, —CF3, —OH, alkoxy, aryl, arylalkyl, fluroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, —N(R40)2, —C(O)OR15A, —C(O)NR15AR16A, —S(O)tNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), halogen, and —NHC(O)NR15AR16A; or
R13A and R14A taken together with the nitrogen to which they are bound in the groups —SO2NR13AR14A and —CONR13AR14A, form an unsubstituted or substituted saturated heterocyclic ring, said ring optionally containing one additional heteroatom selected from the group consisting of: O, S and NR18; wherein there are 1 to 3 substituents on the substituted cyclized R13A and R14A groups, and each substituent is independently selected from the group consisting of: alkyl, aryl, hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, arylalkyl, fluoroalkyl, cycloalkyl, cycloalkylalkyl, heteroaryl, heteroarylalkyl, amino, —C(O)OR15A, —C(O)NR15AR16A, —SOtNR15AR16A, —C(O)R15A, —SO2R15A (provided that R15A is not H), —NHC(O)NR15AR16A, —NHC(O)OR15A, halogen, and a heterocycloalkenyl group
each R15A and R16A is independently selected from the group consisting of: H, alkyl, aryl, arylalkyl, cycloalkyl, heteroaryl, and heteroarylalkyl;
R17 is selected from the group consisting of: —SO2alkyl, —SO2aryl, —SO2cycloalkyl, and —SO2heteroaryl;
R18 is selected from the group consisting of: H, alkyl, aryl, heteroaryl, —C(O)R19, —SO2R19 and —C(O)NR19R20A;
each R19 and R20A is independently selected from the group consisting of: H, alkyl, aryl and heteroaryl;
each R40 is independently selected from the group consisting of: H, alkyl and cycloalkyl; and
t is 1 or 2.

### Claim 57 (depends on 47)

The method of claim 47 wherein said chemokine mediated disease is an angiogenic ocular disease.

### Claim 58 (depends on 57)

The method of claim 57 wherein said angiogenic ocular disease is selected from the group consisting of: ocular inflammation, retinopathy of prematurity, diabetic retinopathy, macular degeneration with the wet type preferred and corneal neovascularization.

### Claim 59 (depends on 50)

The method of claim 50 wherein said cancer is selected from the group consisting of: melanoma, gastric carcinoma or non-small cell lung carcinoma.

### Claim 60 (depends on 51)

The method of claim 51 wherein said cancer is selected from the group consisting of: melanoma, gastric carcinoma or non-small cell lung carcinoma.

### Claim 61 (depends on 60)

The method of claim 60, wherein the anti-cancer agent is selected from the group consisting of: alkylating agents, antimetabolites, natural products and their derivatives, hormones, anti-hormones, anti-angiogenic agents, steroids and synthetics.

### Claim 62 (depends on 61)

The method of claim 61 wherein said anti-angiogenic agent is selected form the group consisting of: Marimastat, AG3340, Col-3, Neovastat, BMS-275291, Thalidomide, Squalamine, Endostatin, SU-5416, SU-6668, Interferon-alpha, Anti-VEGF antibody, EMD121974, CAI, Interleukin-12, IM862, Platelet Factor-4, Vitaxin, Angiostatin, Suramin, TNP470, PTK-787, ZD-6474, ZD-101, Bay 129566, CGS27023A, VEGF receptor kinase inhibitors, taxotere and Taxol.
